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Background

Results

• More than 70% of the HIV population will be above the age of 50 by
the year 2020
• Most are receiving 5 or more medications for common chronic
conditions plus their antiretroviral therapy (ART)1

Table 2. Baseline characteristics of patients pre-simplification
Characteristics
Median age (IQR) - years

• Simplifying ART can improve patient adherence and quality of life2

Male sex - no. (%)

• Limited evidence exists on ART simplification and drug interactions

Race - no. (%)

Purpose
•

•

Total (n = 99)
54 (49-61)
78 (79)

Black or African American

54 (55)

White or Caucasian

38 (38)

The primary objective of this study was to assess changes in the
incidence and severity of drug interactions before and after ART
simplification in treatment experienced patients.

Median duration of infection (IQR) - years

16 (9-22)

Median duration of ART (IQR) - years

10 (5-16)

Describe ART medication class changes and analyze predictors for
achieving drug interaction score reductions.

Median CD4+ cell count (IQR) - cells/mm3

516 (374-737)

HIV-1 RNA < 50 copies/mL - no. (%)

81 (82)

Median number of concomitant medications (IQR)

4 (2-6)

Methods
• Observational, retrospective cohort study of patients on ART for HIV
infection at a single urban center
• Adults receiving at least 1 concomitant medication and undergoing
ART simplification between 6/2014 and 5/2018 were evaluated
• ART regimens pre- and post-simplification were assessed for drug
interactions using the University of Liverpool’s HIV drug-interaction
checker (ULHDIC)

Figure 1. ART Pre- and Post Simplification
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p-value

Concomitant medications*

- 1.03 (CI95 1.01-1.05)

.004

Discontinuing a protease
inhibitor

- 1.47 (CI95 1.26-1.71)

.0001

Switching to bictegravir or
dolutegravir

- 1.27 (CI95 1.09-1.48)

.003

*Score change is predicted per concomitant medication

Conclusion
•

ART simplification decreased the incidence and severity of drugdrug interactions in persons living with HIV (PLWH)

•

Simplification led to lower pill burdens consistent with previous
studies, which may improve treatment convenience and adherence

•

Although there was an overall decrease in drug interaction scores
post-simplification, interactions emerged indicating the continued
importance of ART drug interaction monitoring

•

Future studies can be directed toward analyzing which drug
interactions commonly arise for patients taking simplified ART
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• The average pre-simplification and post-simplification scores were
determined and analyzed using a paired t-test

ULHDIC Interaction
Classification

Predicted Score Change

70

40

Table 1. ULHDIC Interaction Assessment and Scoring

Factor

90

• Scores were generated based on the ULHDIC classification for
interaction potential and total drug interaction scores for each
patient pre- and post-simplification were calculated

• Predictors for achieving drug interaction score reductions were
examined using a multivariable linear regression model

Table 4. Multivariable linear regression model:
Predictors for achieving score reductions with ART simplification
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Limitations
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Table 3. Pre- and post-simplification medication changes
Pre-Switch

Post-Switch

Difference

3.67

2.24

- 1.44*

Switching off PI

3.88

1.25

- 2.63

Switching to an INSTI

3.79

2.31

- 1.47

Average # ART pills/day

3.65

1.52

- 2.13

Mean interaction score

*CI95 [-1.98] – [-0.90]; p = 0.001

•

Subjects were primarily male (79%)

•

Accuracy of the data relied on completeness of the medical record

•

Single centered study could limit the external validity of the results

•

Clinical significance of interactions is not reflected in the drug
interaction score
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